[go: up one dir, main page]

BR0215017A - Lactamas como antagonistas da taquiquinina - Google Patents

Lactamas como antagonistas da taquiquinina

Info

Publication number
BR0215017A
BR0215017A BR0215017-4A BR0215017A BR0215017A BR 0215017 A BR0215017 A BR 0215017A BR 0215017 A BR0215017 A BR 0215017A BR 0215017 A BR0215017 A BR 0215017A
Authority
BR
Brazil
Prior art keywords
het
ring
optionally
heterocycle
optionally substituted
Prior art date
Application number
BR0215017-4A
Other languages
English (en)
Inventor
Donald Stuart Middleton
Alan Stobie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0215017A publication Critical patent/BR0215017A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"LACTAMAS COMO ANTAGONISTAS DA TAQUIQUININA". Os compostos de fórmula (1): ou um seu sal, pró-fármaco, solvato ou polimorfo farmaceuticamente aceitável, em que: R é het^ a^; R^ 1^ é um fenila facultativamente substituído por um ou vários substituintes; m é 1-4; Z é selecionado entre: a) N(R^ 3^)(R^ 4^X) em que X é NR^ 3^R^ 5^, OR^ 3^, Oarila^ 1^, Ohet^ b^, Ohet^ c^, arila^ 1^, het^ b^ ou het^ c^; b) N(R^ 3^)y em que Y é arila^ 1^, het^ b^ ou het^ c^; e c) um heterociclo com 4 a 7 membros, saturado ou parcialmente saturado, e que contém N, em que o referido heterociclo está ligado à ligação alquileno através do átomo de azoto referido, contendo o referido heterociclo facultativamente mais 1 a 3 grupos, cada um deles selecionado independentemente entre C=0, NH, S(O)~ p~; e em que o referido heterociclo é facultativamente: (i) espirofundido com het^ b^, de tal forma que ambos os anéis partilham um átomo; ou (ii) substituído por 1 a 3 grupos; em que R^ 3^ e R^ 6^ são selecionados independentemente entre H e alquila (C~ 1~-C~ 6~); em que R^ 4^ é selecionado entre alquileno (C~ 1~-C~ 6~); em que R^ 5^ é selecionado entre C(O)OR^ 3^, S(O)~ p~R^ 3^, S(O)~ p~arila^ 1^, C(O)R^ 3^ e C(O)NR^ 3^R^ 6^; het^ b^ é um heterociclo com 4 a 7 membros que possui 1 a 3 heteroátomos, cada um deles selecionado independentemente entre N, O e S, sendo o referido N facultativamente substituído com O, contendo o referido anel facultativamente 1 ou 2 grupos C=0, em que o referido anel é saturado ou parcialmente saturado, sendo o referido anel facultativamente benzofundido e sendo o referido anel facultativamente substituído com 1 a 3 substituintes; cada um de het^ a^ e he^ c^ representa independentemente um heterociclo aromático com 5 a 7 membros contendo 1 a 3 heteroátomos selecionados independentemente entre N, O e S, sendo o referido anel facultativamente benzofundido, e em que o referido sistema de anéis, considerado como um todo, é facultativamente substituído com 1 a 3 substituintes; arila^ 1^ é fenila ou naftila, cada um deles facultativamente substituído com 1 a 3 substituintes; p é O,1 ou 2;e n é 0-4; são úteis para o tratamento ou para a prevenção de uma doença para a qual um antagonista NK~ 2~ seja eficaz.
BR0215017-4A 2001-12-18 2002-12-06 Lactamas como antagonistas da taquiquinina BR0215017A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130261.1A GB0130261D0 (en) 2001-12-18 2001-12-18 Lactams as tachykinin antagonists
PCT/IB2002/005234 WO2003051868A1 (en) 2001-12-18 2002-12-06 Lactams as tachykinin antagonists

Publications (1)

Publication Number Publication Date
BR0215017A true BR0215017A (pt) 2004-08-31

Family

ID=9927858

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215017-4A BR0215017A (pt) 2001-12-18 2002-12-06 Lactamas como antagonistas da taquiquinina

Country Status (16)

Country Link
US (1) US7060836B2 (pt)
EP (1) EP1456200A1 (pt)
JP (1) JP2005514389A (pt)
AR (1) AR037852A1 (pt)
AU (1) AU2002366320A1 (pt)
BR (1) BR0215017A (pt)
CA (1) CA2470236A1 (pt)
GB (1) GB0130261D0 (pt)
GT (1) GT200200280A (pt)
HN (1) HN2002000365A (pt)
MX (1) MXPA04005221A (pt)
PA (1) PA8561501A1 (pt)
PE (1) PE20030718A1 (pt)
TW (1) TW200302097A (pt)
UY (1) UY27588A1 (pt)
WO (1) WO2003051868A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199250B2 (en) 2002-12-20 2007-04-03 Battelle Memorial Institute Process for producing cyclic compounds
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1817032A2 (en) * 2004-11-29 2007-08-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1863490A2 (en) * 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Muscarinic modulators
WO2007028638A1 (en) 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
WO2007086559A1 (ja) * 2006-01-27 2007-08-02 Ube Industries, Ltd. テトラヒドロピラン化合物の製造方法
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US20090285862A1 (en) * 2006-05-03 2009-11-19 Cnsbio Pty Ltd. Methods and composition for treatment of inflammatory pain
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US7592345B2 (en) * 2007-06-13 2009-09-22 Hoffmann-La Roche Inc. Piperazine and [1,4]diazepan derivatives as NK antagonists
EP2175886A1 (en) * 2007-06-28 2010-04-21 CNSBio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
WO2009033995A1 (en) * 2007-09-14 2009-03-19 F. Hoffmann-La Roche Ag Piperidine derivatives as nk3 receptor antagonists
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
JP5912169B2 (ja) * 2011-03-23 2016-04-27 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． オピオイド受容体リガンド並びにそれらの使用方法及び製造方法
JP6991993B2 (ja) 2015-12-14 2022-01-13 トレベナ・インコーポレイテッド 痛覚過敏を治療する方法
WO2017126635A1 (ja) * 2016-01-22 2017-07-27 武田薬品工業株式会社 複素環化合物およびその用途
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112321599B (zh) * 2020-11-25 2023-05-30 合肥远志医药科技开发有限公司 一种药物中间体7-氧代-2-氮杂螺[3.5]壬烷的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
GB9600235D0 (en) * 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
PE20030718A1 (es) 2003-08-18
GT200200280A (es) 2003-07-11
EP1456200A1 (en) 2004-09-15
PA8561501A1 (es) 2003-07-28
UY27588A1 (es) 2003-07-31
TW200302097A (en) 2003-08-01
WO2003051868A1 (en) 2003-06-26
JP2005514389A (ja) 2005-05-19
CA2470236A1 (en) 2003-06-26
GB0130261D0 (en) 2002-02-06
AU2002366320A1 (en) 2003-06-30
US7060836B2 (en) 2006-06-13
AR037852A1 (es) 2004-12-09
HN2002000365A (es) 2003-07-23
US20040132710A1 (en) 2004-07-08
MXPA04005221A (es) 2004-08-19

Similar Documents

Publication Publication Date Title
BR0215017A (pt) Lactamas como antagonistas da taquiquinina
PA8431301A1 (es) Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion
UY26872A1 (es) Derivados de la 4- fenil piridina
AR035759A1 (es) Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR055878A1 (es) Derivados de ciclopropanocarboxamida
BR0212760A (pt) Compostos quìmicos
CY1118723T1 (el) Ενωσεις βενζοθειαζολιου και αζαβενζοθειαζολιου χρησιμες ως αναστολεiς κινασης
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
AR049333A1 (es) Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
BR0213393A (pt) Derivados de éter alquìlico e de alquilamida ou seus sais, processos para produzir um derivado de éter alquìlico, e, composição farmacêutica
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CY1108256T1 (el) Νεα παραγωγα κουιναζολινης
BRPI0509307A (pt) compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
HN1998000034A (es) Quinoxalinadionas
ATE464286T1 (de) Cyclopropanderivate und ihre pharmazeutische verwendung
BRPI0512615A (pt) compostos de sulfonamida
AR038881A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AR054000A1 (es) Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2047 DE 30/03/2010.